-+ 0.00%
-+ 0.00%
-+ 0.00%

ORIC Pharmaceuticals Q3 net loss widens 48% to $48.08 million

PUBT·11/16/2026 21:10:03
ORIC Pharmaceuticals Q3 net loss widens 48% to $48.08 million
  • ORIC Pharmaceuticals’ third-quarter 2026 net loss widened 48% year over year to $48.08 million.
  • Research and development expenses rose 51% to $43.36 million, primarily due to higher external spending advancing rinzimetostat.
  • Cash and investments totaled $345.4 million at September 30, 2026, with operating runway expected into the second half of 2028.
  • ORIC initiated the Himalayas-1 Phase 3 trial of rinzimetostat in previously treated prostate cancer, supported by Bayer’s darolutamide supply agreement.
  • The Redwood-1 Phase 3 trial of enozertinib in first-line EGFR atypical lung cancer is expected to begin in first-half 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oric Pharmaceuticals Inc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611161605PRIMZONEFULLFEED9878779) on November 16, 2026, and is solely responsible for the information contained therein.